-
- Ryuta Shigefuku, Kyoko Yoshikawa, Mone Tsukimoto, Hirono Owa, Yasuyuki Tamai, Masahiko Tameda, Suguru Ogura, Ryosuke Sugimoto, Hideaki Tanaka, Akiko Eguchi, Kazushi Sugimoto, Hiroshi Hasegawa, Motoh Iwasa, and Hayato Nakagawa.
- Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Japan.
- Intern. Med. 2023 Feb 15; 62 (4): 539543539-543.
AbstractA 70-year-old man was diagnosed with hepatocellular carcinoma (HCC) with portal vein invasion and lung metastases, for which atezolizumab plus bevacizumab (ATZ/BEV) was initiated. After two months, computed tomography revealed tumor growth accompanied by ascites, right ventricular invasion, exacerbation of the lung metastases, and main portal vein invasion. However, continuation of ATZ/BEV caused remarkable size reductions in all lesions, finally resulting in the disappearance of the vascular invasion and lung metastases after nine cycles of treatment. The tumor growth was considered to reflect pseudoprogression, which is difficult to distinguish from hyperprogression. We herein report a remarkable HCC case of pseudoprogression on ATZ/BEV.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:

- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.